(Il Sole 24 Ore Radiocor) - Milano, 31 mar - The US biotechnology firm Biogen said that it has reached a defintive agreement to buy Apellis Pharmaceuticals for 41.00 dollars per share in cash at closing, or approximately 5.6 billion dollars.

Apellis stockholders will also receive a nontransferable contigent value rights (CVR) for each share held, entitling the holder to receive two payments of 2 dollars per share, contingent on certain annual global net sales thresholds being met for the drug Syfovre, which was approved by the US Food and Drug Administration in geographic atrophy, an immune-mediated retinal disease.

Bringing together the companies' commercialization capabilities will maximize the potential of both Biogen's Empaveli and Syfovre, "while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3," it noted.

Empaveli was approved the FDA in three indications, including.

two rare kidney diseases.

(RADIOCOR) 31-03-26 14:14:05 (0471) 5 NNNN